drugset / Trial / NCT07655570

Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma

NCT07655570

Phase 2 Not yet recruiting 10 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been treated with taxane-based chemotherapy.

Timeline

Start
2026-11-30
Primary completion
2027-05-11
Completion
2029-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous

Indications